Verona Pharma
plc
(“Verona Pharma” or the
“Company”)
Director
Dealing
7 July 2015, Cardiff –
Verona Pharma plc (AIM: VRP) today received notification that
Stuart Bottomley, Non-Executive
Director of the Company, transferred 500,000 ordinary shares
of 0.1 pence each of the Company
(“Ordinary Shares”) for nil consideration to his son.
Following the transfer, Stuart
Bottomley has a total interest of 19,500,000 Ordinary
Shares, representing 1.93% of the total voting rights.
-Ends-
For further information please
contact:
Verona Pharma plc
Jan-Anders Karlsson, CEO |
Tel: +44 (0)20 3283 4200 |
|
|
|
|
N+1 Singer
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
|
|
|
|
FTI Consulting
Julia Phillips / Simon Conway |
Tel: +44 (0)20 3727 1000 |
|
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as COPD, asthma and cystic fibrosis. Verona
Pharma's lead drug, RPL554, is a first-in-class drug currently in
Phase II trials as a nebulised treatment for acute exacerbations of
COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has
both bronchodilator and anti-inflammatory effects, which are
essential to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader franchise around RPL554 to
maximise its value, both to patients and to investors. This
includes the very significant markets for COPD and asthma
maintenance therapy. The Company is also exploring the potential of
the drug in different diseases, such as cystic fibrosis, where it
is in pre-clinical testing.